Daunorubicin HCl

For research use only. Not for use in humans.

Catalog No.S3035 Synonyms: Daunomycin HCl

27 publications

Daunorubicin HCl Chemical Structure

Molecular Weight(MW): 563.98

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 90 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Daunorubicin HCl has been cited by 27 publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay.
Targets
DNA synthesis [1]
(Cell-free assay)
20 nM(Ki)
In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. [1] Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. [2] Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
P388 leukemia cell line MX;DfZRwfG:6aXRCpIF{e2G7 MW\Dc41xd3WwZDD3ZZMh\X[jbIXheIVlKG[xcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBROzh6IHzleYtmdWmjIHPlcIwhdGmwZTygTWM2OD1|IH7N M1jIUFExPDd7Mkm3
HL60 cells MnLNSpVv[3Srb36gZZN{[Xl? MlzrTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCKTE[wJINmdGy|LDDJR|UxRTBwMEC1JO69VQ>? NWrCdHFNOTJ6N{e1PVM>
human epidermoid carcinoma cell line KB-3-1 MYHDfZRwfG:6aXRCpIF{e2G7 MXvJckB3cXS{bzDjfZRwfG:6aXOgZYN1cX[rdImge4F{KGW4YXz1ZZRm\CC3c3nu[{B1cGViaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscEBtcW6nIFvCMVMuOSxiSVO1NF04KG6P MkG4NVI1PDN5NkO=
human K562 cells M1zITGN6fG:2b4jpZ:Kh[XO|YYm= MmTOO|IhcA>? NHjF[HREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBZXFRiYYPzZZktKEeLNUC9O{41KG6P NUOw[|F[OjB3OUG2O|g>
Dx5 w/PSC cell lines MoDaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfoWIhmKGOxbYDveY5lKHejczDleoFtfWG2ZXSg[o9zKHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kBFgDVidz;QV2Mh[2WubDDsbY5meyC3c3nu[{BOXFRiYYPzZZktKEmFNUC9NVQhdk1? NYq1[FdxOTB4OUi0OFk>
MDA MB 361(mammary carcinoma cell line) NWSyZ2NYS3m2b4TvfIlkyqCjc4PhfS=> MWXUbIUh[2:vcH;1coQhf2G|IITld5Rm\CCob4KgbY51emGlZXzseYxieiCleYTveI95cWOrdImgZYdicW6|dDDNSGEhVUJiM{[xLI1idW2jcomgZ4Fz[2mwb33hJINmdGxibHnu[Ukh\XiycnXzd4lv\yCOYXPaJEhj\XSjLXfhcIFkfG:|aXThd4UqNCCLQ{WwQVE4KG6P MWKxNFM6PTR7MB?=
human MDA-MB-231 cells M{jzdGN6fG:2b4jpZ:Kh[XO|YYm= M4TEWFczKGh? NIjvbWpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVAvODJizszN NETkeY0yQTl4OEK1PC=>
MES-SA uterine tumor cell lines MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfOU4g4XGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCPRWOtV2EhfXSncnnu[UB1fW2xcjDj[YxtKGyrbnXzJJV{cW6pIF3UWEBie3OjeTygTWM2OD1yLkCyNUDPxE1? NULKfZd{OTB4OUi0OFk>
murine L1210 leukemia cells NUjHN5dxTnWwY4Tpc44h[XO|YYm= MW\Jcohq[mm2b4L5JIFkfGm4aYT5JJdieyCvZXHzeZJm\CCjZ3HpcpN1KG23cnnu[UBNOTJzMDDs[ZVs\W2rYTDj[YxteyxiSVO1NF0{OCCwTR?= MofoPVc{OzR6Mx?=
HL60 cells MYLGeY5kfGmxbjDhd5NigQ>? NF32bJRKdiC4aYTyc{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlv\HWlZTDhdI9xfG:|aYOgbY4hUEx4MDDj[YxteyxiQVO1NF0xNjB2IN88US=> M2nZdFEzQDd5NUmz
CCRF-CEM (human lymphoblastic leukemic) cells NIfmd5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPMWmpKdiC4aYTyc{Boem:5dHigbY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGNEWkZvQ1XNJEhpfW2jbjDsfY1xcG:kbHHzeIlkKGyndXvlcYlkMSClZXzsd{whUUR3ME2wMlA1KM7:TR?= NGjyVIo3QTVzMES5
mouse NIH/3T3 cells NI\UTGhEgXSxdH;4bYPDqGG|c3H5 MlGwO|IhcA>? NWDReIpoUW62cnnud4lkKGO7dH;0c5hq[2m2eTDh[4FqdnO2IIfpcIQhfHmyZTDtc5V{\SCQSVivN3Q{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wOFQh|ryP NV\sVWl1OTh7NUSwOFA>
human prostate cancer HTB-81 cells M1zuemN6fG:2b4jpZ:Kh[XO|YYm= NEfEephEgXSxdH;4bYNqfHlidHjheEBk[XW|ZXSgZUA2OCVicnXkeYN1cW:wIHnuJIFje2:{YnHuZ4Uh[XRiNEmwJI5uKGmwIHj1cYFvKHC{b4P0ZZRmKGOjbnPldkBJXEJvOEGgZ4VtdHNidYPpcochVVSVIHHzd4F6NCCHQ{WwQVAvODV6IN88US=> MoH4NVExOjB{OEW=
human breast carcinoma line cells NX\RTXRKTnWwY4Tpc44h[XO|YYm= NWr3epk6[2:vcH;1coQhf2G|IITld5Rm\CCrbjD2bZRzdyCob4KgbY5pcWKrdHnvckBi[3Srdnn0fUBi\2GrboP0JIEhe2Wwc3n0bZZmKGi3bXHuJIJz\WG|dDDjZZJkcW6xbXGgcIlv\SClZXzsd{whUUN3ME2wMlA3KM7:TR?= NIHiUXU6OjV6M{Wx
MCF-7 cells MWrDfZRwfG:6aXRCpIF{e2G7 M{S4RWNwdXCxdX7kJJdieyC2ZYP0[YQh\m:{IHn0d{B1d3irY3n0fUBi\2GrboP0JIh2dWGwIHLy[YF{fCClYX7j[ZIh[2WubIOoUWNHNTdrLDDJR|UxRTBwME[g{txO NWnOXmNZQTV2OEiyNC=>
human HT-29 cells MX7DfZRwfG:6aXRCpIF{e2G7 MXS3NkBp NFK0cmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC3JO69VQ>? MoD3NVk6Pjh{NUi=
human uterine sarcoma cell line MES-SA M13KNWN6fG:2b4jpZ:Kh[XO|YYm= NWfHWYRGUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczDleoFtfWG2ZXSgeZNqdmdidHjlJIh2dWGwIIX0[ZJqdmVic3HyZ49u[SClZXzsJIxqdmViTVXTMXNCNCCLQ{WwQVAvODdizszN MUmxNlQ1Ozd4Mx?=
human MRC5 cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 M4XuRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWLDOUBk\WyuczDifUBZXFRiYYPzZZktKEmFNUC9NE4xPzhizszN Mle0NlU1Pjd{OUG=
MDA435/LCC6 cells NV75S5duWHKxbHnm[ZJifGmxbjDhd5NigQ>? NXjvTWRJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBOTEF2M{WvUGNEPiClZXzsd{BjgSCHTFnTRUwhUUN3ME2wMlA4QSEQvF2= MVmxO|E2PDVyNR?=
human A549 cells Mn;YR5l1d3SxeHnjxsBie3OjeR?= NXfqZWFvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OD1yLkC4JO69VQ>? NGHj[nYyQTl4OEK1PC=>
Jurkat T lymphocytes NVLpSGpqS3m2b4TvfIlkyqCjc4PhfS=> NV;LSmdoS3m2b4TvfIlkcXS7IHHnZYlve3RiSoXyb4F1KFRibIntdIhw[3m2ZYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODh{NjFOwG0> M2rOSlE3OzZ4NkCy
human DU145 cells NGj6dodRem:uaX\ldoF1cW:wIHHzd4F6 MkjNO|IhcA>? M1jxS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkC5JO69VQ>? NWDSXG14OjJ{NkCxOlY>
human MDA-MB-231 cells NFLWS3hRem:uaX\ldoF1cW:wIHHzd4F6 MnS3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGK7IGjUWEBie3OjeTygTWM2OD1yLkC5NUDPxE1? NWLUfWEyOjV2NkeyPVE>
human H1299 cells NEOxWnJRem:uaX\ldoF1cW:wIHHzd4F6 NUHsXFBLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDINVI6QSClZXzsd{BjgSC[VGSgZZN{[XluIFnDOVA:OC5yOU[g{txO MVqyOVQ3PzJ7MR?=
human HL60 cells Mnr1R5l1d3SxeHnjxsBie3OjeR?= NHmyc5g1QCCq NXzQUmtwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nlidIL5dIFvKGKudXWgd5RicW6rbnetZoF{\WRiaHXtc4N6fG:vZYTybYMh[W6jbInzbZMtKEeLNUC9NE4yKM7:TR?= NGfodYgzPTh5NEOzOS=>
human LNCAP cells NELmemlEgXSxdH;4bYPDqGG|c3H5 MofmOEBl[Xm| M1Tnb2N6fG:|dHH0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNUDPxE1? NF7xPHMzOjR6MES5OS=>
NCI-H69 cell line M{XDTXBzd2yrZnXyZZRqd25iYYPzZZk> NEDIWWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIRzfWdic3Xud4l1cX[nIF7DTU1JPjliY3XscEBtcW6nIHL5JGFt[W2jcjDCcJVmKGG|c3H5MEBKSzVyPUCuNUDPxE1? M3O0XFE4Ojh4M{mz
human A2780 cells MXrDfZRwfG:6aXRCpIF{e2G7 MWG3NkBp MojHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEyPzR7IN88US=> NHfaRpMyPzh7MEC5OC=>
human HT-29 cells MXnQdo9tcW[ncnH0bY9vKGG|c3H5 M{\sSVk3KGh? NXrYRmllSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVM{KM7:TR?= MViyO|c5PDR7
B16 mouse melanoma cells NFXJdIVEgXSxdH;4bYPDqGG|c3H5 NYi2cGFJS3m2b4TvfIlkcXS7IIToZZQh[2G3c3XkJIEhPTBnIILl[JVkfGmxbjDpckBi[nOxcnLhcoNmKGG2IES5NEBvdSCrbjDCNVYhdW:3c3WgcYVt[W6xbXGgZ4VtdHNidYPpcochVVSVIHHzd4F6NCCHQ{WwQVAvOTZizszN NIfqUWYyOTB{MEK4OS=>
human SKMES1 cells M3f5XXBzd2yrZnXyZZRqd25iYYPzZZk> NXPYR3NVPzJiaB?= MlmxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVS13FV|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkG3JO69VQ>? NGHObmYzOjJ4MEG2Oi=>
human fibroblast (NHF) cells M2HJOWN6fG:2b4jpZ:Kh[XO|YYm= NWT2WGdCS3m2b4TvfIlkcXS7IIToZZQh[2G3c3XkJIEhPTBnIILl[JVkfGmxbjDpckBi[nOxcnLhcoNmKGG2IES5NEBvdSCrbjDuc5Ju[WxiaIXtZY4h\mmkcn;icIF{fCBqTljGLUBk\WyuczD1d4lv\yCPVGOgZZN{[XluIFXDOVA:OC5{MjFOwG0> MkH6NVExOjB{OEW=
mouse L1210 cells NUixSXZ3TnWwY4Tpc44h[XO|YYm= NXzk[YZnUW6qaXLpeIlwdiCxZjDSUmEhe3mwdHjld4l{KGmwIH3veZNmKExzMkGwJINmdGy|LDDFSFUxRTBwMkOg{txO NGPIbWE3QTB7OUm=
human NCI-H460 cells MYTGeY5kfGmxbjDhd5NigQ>? NULOcWVbSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy|LDDJR|UxRTBwM{ig{txO MYmyNVU6QTByMB?=
human MCF7 cells NUnYVJFHS3m2b4TvfIlkyqCjc4PhfS=> MWC0JIRigXN? NVzSPXdyS3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQh|ryP M1G5VlIzPDhyNEm1
human SF268 cells M1PZO2Z2dmO2aX;uJIF{e2G7 MWXBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yOlgh[2WubIOsJGlEPTB;MD62JO69VQ>? NH24PYkzOTV7OUCwNC=>
human KB cells MVnDfZRwfG:6aXRCpIF{e2G7 NEfCSos1QCCq MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwNkSg{txO M1;T[|IxOzZ|MUSy
human HepG2 cells MljLR5l1d3SxeHnjxsBie3OjeR?= MlLwNlQhcA>? MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRUKGG|c3H5MEBKSzVyPUCuO{DPxE1? MnizNlExQTRyNEm=
mouse L5178Y cells MY\DfZRwfG:6aXRCpIF{e2G7 M4TabFI1KGh? M2P3N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGw2OTd6WTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvPzJizszN NYP3UnJIOjNzOUm0O|k>
human MCF7 cells M17EbWN6fG:2b4jpZ:Kh[XO|YYm= MWq3NkBp MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO|YYmsJGdKPTB;MD64OkDPxE1? Mli4NlA2QTF4N{i=
human MRC5 cells NFjC[mFRem:uaX\ldoF1cW:wIHHzd4F6 M2LScGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWLDOUBk\WyuczygTWM2OD1yLki4JO69VQ>? M3z6XVIyPTl7MECw
MDA435/LCC6 cells MULQdo9tcW[ncnH0bY9vKGG|c3H5 NWLZZXZrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBufWy2aXTyeYchemW|aYP0ZY51KE2GQUSzOU9NS0N4IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvQTd5IN88US=> MWexO|E2PDVyNR?=
mouse NIH/3T3 cells M2O4XGN6fG:2b4jpZ:Kh[XO|YYm= MVO3NkBp M161WWlvfHKrboPpZ{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy|IH;2[ZJmgHC{ZYPzbY5oKE2GUkGgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkCxJO69VQ>? MmT2NVg6PTRyNEC=
human Detroit 551 cells MUjDfZRwfG:6aXRCpIF{e2G7 NXHNVHZ5PzJiaB?= MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDE[ZRzd2m2IEW1NUBk\WyuczDh[pRmeiB5MjDodpMh[nliWGTUJIF{e2G7LDDHTVUxRTFwN{eg{txO NYTESGFyOjB3OUG2O|g>
mouse DA-3 cells MlXZR5l1d3SxeHnjxsBie3OjeR?= MUCyOEBp MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDERU0{KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDYWHQh[XO|YYmsJGlEPTB;MT65JO69VQ>? NHXuPY0zPDlyME[2PC=>
african green monkey Vero cells M2XRRWN6fG:2b4jpZ:Kh[XO|YYm= NU\KeGt{OyCmYYnz NXPSOW5DS3m2b4TvfIlkcXS7IHHnZYlve3RiYX\ybYNidiCpcnXlckBud26tZYmgWoVzdyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRUKGG|c3H5MEBKSzVyPUKuOUDPxE1? M13CNVIyODl2MES5
Dx5 cell lines MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUXIRWpyXGinIHPvcZBwfW6mIIfhd{BmfmGudXH0[YQh\m:{IITo[UBoem:5dHigbY5pcWKrdHnvckBw\iCGeEWgZ4VtdCCuaX7ld{B2e2mwZzDNWHQh[XO|YYmsJIlkPTB;MjFOwG0> MUWxNFY6QDR2OR?=
human HeLa3 cell line MVXDfZRwfG:6aXRCpIF{e2G7 NX3PXJIyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYUOgZ4VtdCCuaX7lJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjl4IN88US=> NEfBdFAyPjl2MkCzOy=>
mouse L5178Y cells NF30c4xEgXSxdH;4bYPDqGG|c3H5 MXKyOEBp NIPsVXlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNPTF5OGmgZ4VtdHNiZYjwdoV{e2mwZzDwMYdxKGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{44OyEQvF2= M2jCTFI{OTl7NEe5
human CRL7761 cells NFThcldEgXSxdH;4bYPDqGG|c3H5 MWizJIRigXN? MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDVmw4PzZzIHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFNiYYPzZZktKEmFNUC9NVAvPSEQvF2= NV7sOllYOjFyOUSwOFk>
human A2780/ADR cells NUCyO4Z5S3m2b4TvfIlkyqCjc4PhfS=> NWDHT41KPzJiaB?= MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OC:DRGKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yQC54MkC5JO69VQ>? M1fRc|E4QDlyMEm0
human SKOV3 cells MUPDfZRwfG:6aXRCpIF{e2G7 M1jTflI1KGh? MmrkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHhVXCCjc4PhfUwhUUN3ME2yNE43KM7:TR?= M1L2OFI1QTByNk[4
human ES2 cells NXqwTpZ2S3m2b4TvfIlkyqCjc4PhfS=> NXjiN3lrOjRiaB?= NH;SOopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGWzJiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHhVXCCjc4PhfUwhUUN3ME2yOU42KM7:TR?= MlroNlQ6ODB4Nki=
CEM cells NYLWT41NS3m2b4TvfIlkyqCjc4PhfS=> NIGyVXc4OiCq MkLHR5l1d3SxeHnjbZR6KGGpYXnud5QhS0WPIHPlcIx{KGGodHXyJFczKGi{cx?= MoG5NVc3ODh|OU[=
HOS cells M4\Y[GN6fG:2b4jpZ:Kh[XO|YYm= MoWyO|IhcA>? NI[4RllEgXSxdH;4bYNqfHliYXfhbY5{fCCKT2OgZ4VtdHNiYX\0[ZIhPzJiaILz MUixO|YxQDN7Nh?=
mouse DA-3 cells NFuzPWtEgXSxdH;4bYPDqGG|c3H5 NFG2U5EzOCEQvF2= MYG2NEBucW6| NYDsc4NNS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTEFvMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOjBidV2gZYZ1\XJiNkCgcYlveyCkeTDYWHQh[XO|YYm= MlG1NlQ6ODB4Nki=
human G361 cells MmDmR5l1d3SxeHnjxsBie3OjeR?= M{nHdlczKGh? M4HxbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGc{PjFiY3XscJMh[W[2ZYKgO|IhcHK| MV2xO|YxQDN7Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / p-ATR / ATR ; 

PubMed: 26727128     


After Caco-2 cells were treated with or without 1 μ M daunorubicin, whole cell extracts were collected at 1, 3, 6, 12, 24, and 48 h and immunoblotted for Chk1, p-Chk1, ATR, and p-ATR. β-actin served as the loading control.

26727128
Immunofluorescence
p-Chk1; 

PubMed: 26727128     


Caco-2 cells were treated with or without 1 μ M daunorubicin for 48 h, and then fixed and stained with anti-p-Chk1 antibody and DAPI. Images were collected under a fluorescence microscope. Scale bar = 10 μm. 

26727128
Growth inhibition assay
Cell viability; 

PubMed: 30745844     


(A) Viability of AML cell lines under different concentrations of Dnr according to the CCK-8 assay. (B) IC50 of AML cell lines calculated according to the result of the CCK-8 assay.

30745844

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (177.31 mM)
Water 100 mg/mL (177.31 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 563.98
Formula

C27H29NO10 . HCl

CAS No. 23541-50-6
Storage powder
in solvent
Synonyms Daunomycin HCl
Smiles Cl.COC1=C2C(=O)C3=C(C(=C4CC(O)(CC(OC5CC(N)C(O)C(C)O5)C4=C3O)C(C)=O)O)C(=O)C2=CC=C1

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03878927 Recruiting Drug: CPX-351|Drug: Gemtuzumab Ozogamicin Acute Myeloid Leukemia Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer August 23 2019 Phase 1
NCT03896269 Recruiting Drug: Liposome-encapsulated Daunorubicin-Cytarabine Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 14 2019 Phase 1
NCT02914977 Active not recruiting Drug: Daunorubicin Acute Lymphocytic Leukemia|Acute Myeloid Leukemia Tara Lin|University of Kansas Medical Center November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Daunorubicin HCl | Daunorubicin HCl supplier | purchase Daunorubicin HCl | Daunorubicin HCl cost | Daunorubicin HCl manufacturer | order Daunorubicin HCl | Daunorubicin HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID